Drug Trial Radar · NCT05109650
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients
Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Feb 28, 2022
Primary completion
Mar 23, 2023
Study completion Feb 2, 2024
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase 1 dose-escalation study of BAT6026, an OX40 monoclonal antibody, combined with the anti-PD-1 IgG4 monoclonal antibody BAT1308 in subjects with advanced solid tumours. After a screening period of up to 28 days, qualified subjects will be enrolled to receive their assigned dose regimen until disease progression or intolerable toxicity, withdrawal of consent, per Investigator decision, or end of study, whichever occurs first. The maximum treatment duration is 1 year. Subjects who remain on treatment in the absence of disease progression for more than 1 year may continue to receive study drug for the next cycle at the maximum of 2 years.
Conditions
- Advanced Solid Tumour
Interventions
BAT6026Drug
IV infusions
BAT1308Drug
Ⅳ infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT)Time frame: the first cycle of 21 days for monotherapy and the second cycle of another 21 days for combination therapy
- Serious adverse event(SAE)Time frame: Adverse events will be collected from the time of informed consent to 90 days after the last dose or until the initiation of a new cancer treatment.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
St George Private Hospital
Kogarah, Australia
Blacktown Cancer and Haematology Centre
Sydney, Australia
Scientia Clinical Research Limited
Sydney, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.